Law360, New York (April 28, 2009, 12:00 AM ET) -- A 38-state coalition has launched an investigation into Bristol-Myers Squibb Co. for alleged violations of state consumer protection laws in its marketing of anti-psychotic Abilify.
In a 10-Q form filed Tuesday with the U.S. Securities and Exchange Commission, the company disclosed the existence of the multistate investigation into its marketing of Abilify, an anti-psychotic.
In March, Bristol-Myers received a letter from the Delaware Attorney General's Office notifying it of the investigation, it said in the filing.
Bristol-Myers did not disclose details of the investigation in the...
Dozens Of States Probe Abilify Marketing
To view the full article, take a free trial now.
